The accomplices: Heparan sulfates and N-glycans foster SARS-CoV-2 spike:ACE2 receptor binding and virus priming.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
22 Oct 2024
Historique:
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: ppublish

Résumé

Although it is well established that the SARS-CoV-2 spike glycoprotein binds to the host cell ACE2 receptor to initiate infection, far less is known about the tissue tropism and host cell susceptibility to the virus. Differential expression across different cell types of heparan sulfate (HS) proteoglycans, with variably sulfated glycosaminoglycans (GAGs), and their synergistic interactions with host and viral N-glycans may contribute to tissue tropism and host cell susceptibility. Nevertheless, their contribution remains unclear since HS and N-glycans evade experimental characterization. We, therefore, carried out microsecond-long all-atom molecular dynamics simulations, followed by random acceleration molecular dynamics simulations, of the fully glycosylated spike:ACE2 complex with and without highly sulfated GAG chains bound. By considering the model GAGs as surrogates for the highly sulfated HS expressed in lung cells, we identified key cell entry mechanisms of spike SARS-CoV-2. We find that HS promotes structural and energetic stabilization of the active conformation of the spike receptor-binding domain (RBD) and reorientation of ACE2 toward the N-terminal domain in the same spike subunit as the RBD. Spike and ACE2 N-glycans exert synergistic effects, promoting better packing, strengthening the protein:protein interaction, and prolonging the residence time of the complex. ACE2 and HS binding trigger rearrangement of the S2' functional protease cleavage site through allosteric interdomain communication. These results thus show that HS has a multifaceted role in facilitating SARS-CoV-2 infection, and they provide a mechanistic basis for the development of GAG derivatives with anti-SARS-CoV-2 potential.

Identifiants

pubmed: 39401361
doi: 10.1073/pnas.2404892121
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
spike protein, SARS-CoV-2 0
Heparitin Sulfate 9050-30-0
Polysaccharides 0
ACE2 protein, human EC 3.4.17.23
Glycosaminoglycans 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2404892121

Subventions

Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : 458623378
Organisme : Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
ID : 57507871

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Giulia Paiardi (G)

Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg 69118, Germany.
Heidelberg University, Heidelberg 69117, Germany.
Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg 69120, Germany.

Matheus Ferraz (M)

Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg 69118, Germany.
Department of Virology, Aggeu Magalhães Institute, Oswaldo Cruz Foundation, Recife, PE 50740-465, Brazil.
Department of Fundamental Chemistry, Federal University of Pernambuco, Recife, PE 50740-560, Brazil.

Marco Rusnati (M)

Macromolecular Interaction Analysis Unit, Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, Brescia 25123, Italy.

Rebecca C Wade (RC)

Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies (HITS), Heidelberg 69118, Germany.
Heidelberg University, Heidelberg 69117, Germany.
Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg 69120, Germany.
Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg 69120, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH